Pamela Wapnick, Chief Financial Officer of Metagenomi, Inc. ($MGX), sold shares on the open market four times in the last 365 days, totaling nearly $11,000. Her most recent sale occurred on March 5, 2026. These sales rank her 11,253rd among 11,678 individual insiders by total amount sold, well below the average of $8.6 million per insider and 6.4 transactions. Wapnick made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | Metagenomi Therapeutics, Inc. | $MGX | Wapnick Pamela | Chief Financial Officer | A | Stock Option (Right to Buy) | 144000 | $0.00 | 144,000.0000 | 37,546,751 | 9999.99% | 0.38% |
| April 1, 2026 | Metagenomi Therapeutics, Inc. | $MGX | Wapnick Pamela | Chief Financial Officer | A | Common Stock | 24000 | $0.00 | 211,375.0000 | 37,546,751 | 12.81% | 0.06% |
| March 5, 2026 | Metagenomi Therapeutics, Inc. | $MGX | Wapnick Pamela | Chief Financial Officer | S | Common Stock | 1581 | $1.60 | 187,375.0000 | 37,546,751 | 0.84% | 0.00% |
| Dec. 5, 2025 | Metagenomi Therapeutics, Inc. | $MGX | Wapnick Pamela | Chief Financial Officer | S | Common Stock | 1576 | $1.77 | 188,956.0000 | 37,546,751 | 0.83% | 0.00% |
| Sept. 5, 2025 | Metagenomi Therapeutics, Inc. | $MGX | Wapnick Pamela | Chief Financial Officer | S | Common Stock | 1576 | $1.81 | 70,532.0000 | 1,870,923 | 2.19% | 0.08% |
| Dec. 1, 2025 | Metagenomi Therapeutics, Inc. | $MGX | Wapnick Pamela | Chief Financial Officer | A | Common Stock | 120000 | $1.60 | 190,532.0000 | 37,546,751 | 170.14% | 0.32% |
| June 6, 2025 | Metagenomi Therapeutics, Inc. | $MGX | Wapnick Pamela | Chief Financial Officer | S | Common Stock | 1576 | $1.75 | 72,108.0000 | 1,870,923 | 2.14% | 0.08% |
| April 1, 2025 | Metagenomi Therapeutics, Inc. | $MGX | Wapnick Pamela | Chief Financial Officer | A | Common Stock | 14000 | $0.00 | 73,684.0000 | 1,870,923 | 23.46% | 0.75% |
| April 1, 2025 | Metagenomi Therapeutics, Inc. | $MGX | Wapnick Pamela | Chief Financial Officer | A | Stock Option (Right to Buy) | 84000 | $0.00 | 84,000.0000 | 1,870,923 | 9999.99% | 4.49% |
| March 5, 2025 | Metagenomi Therapeutics, Inc. | $MGX | Wapnick Pamela | Chief Financial Officer | S | Common Stock | 1808 | $1.87 | 59,684.0000 | 1,870,923 | 2.94% | 0.10% |
| Dec. 5, 2024 | Metagenomi Therapeutics, Inc. | $MGX | Wapnick Pamela | Chief Financial Officer | S | Common Stock | 1559 | $1.86 | 61,492.0000 | 3,884,740 | 2.47% | 0.04% |
| Sept. 5, 2024 | Metagenomi Therapeutics, Inc. | $MGX | Wapnick Pamela | Chief Financial Officer | S | Common Stock | 6265 | $2.88 | 63,051.0000 | 3,884,740 | 9.04% | 0.16% |
| April 1, 2024 | Metagenomi Therapeutics, Inc. | $MGX | Wapnick Pamela | Chief Financial Officer | A | Stock Option (Right to Buy) | 291450 | $0.00 | 291,450.0000 | 3,884,740 | 9999.99% | 7.50% |
| April 1, 2024 | Metagenomi Therapeutics, Inc. | $MGX | Wapnick Pamela | Chief Financial Officer | A | Common Stock | 69316 | $0.00 | 69,316.0000 | 3,884,740 | 9999.99% | 1.78% |